Principal Investigators


Ira Hebold Haraldsen

Institution


Oslo University Hospital

Contact information of lead PI


Country


Norway

Title of project or programme


Development of a Novel F18-PET tracer for early diagnosis of Alzheimers Dementia

Source of funding information


RCN

Total sum awarded (Euro)


€ 731,200

Start date of award


01/05/2014

Total duration of award in years


3.0

The project/programme is most relevant to:


Alzheimer's disease & other dementias

Keywords


Research Abstract


Our primary objective is to develop a F18-GnRH PET-tracer for pre-symptomatic diagnosis of AD.
Our secondary objectives are:
Development of a 3rd generation library of compounds to optimize the brain uptake, specific binding and metabolic stability.
Screen for lead candidates according to selection criteria
Estimate the binding potential of GnRH tracers in rodent brain sections (Bmax/Kd) to assess the expected signal strength of specific binding of the tracer.
Estimate the binding potential of GnRH tracer s in human brain sections (Bmax/Kd) (as above).
Dynamic in vivo PET in rats (correlation to receptor distribution as measured by immunohistochemical staining patterns).
Dynamic displacement / pre-blockage of tracer uptake by treatment with a non-radioac tive GnRH-affine compound (for quantification/specificity of signal).
concentrations.
Outsourcing of ADMET-studies (Absorption, distribution, metabolism, excretion, toxicity) for preparation of clinical applications

Lay Summary


Further information available at:

Export as PDF